<DOC>
	<DOCNO>NCT01755325</DOCNO>
	<brief_summary>It open-label , randomize , double blind , placebo-controlled parallel-group , multi-center study evaluate efficacy safety Compound realgar formula Realgar-Indigo naturalis Tablet combine Imatinib compare imatinib alone adult patient diagnose Philadelphia chromosome-positive ( Ph+ ) chronic myelogenous leukemia chronic phase ( CML-CP ) .</brief_summary>
	<brief_title>Phase III Study Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib Adult CML-CP Patients With Ph+</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient , age &gt; = 18 year &lt; = 75 year . 2 . Eastern Cooperative Oncology Group （ECOG） performance status ( PS ) score 0 , 1 , 2 . 3 . Diagnosis chronic myelogenous leukemia chronic phase confirmation Philadelphia chromosome positive . ( Ph+ CMLCP ) 4 . Ph+ Chronic myelogenous leukemia chronic phase patient within first 12 month diagnosis . 5 . Adequate end organ function define : ( 1 ) . Alanine transaminase（ALT） , Aspartate transaminase（AST） &lt; =2.5 x upper limit normal（ULN） . ( 2 ) . Total bilirubin &lt; = 1.5 x ULN . ( 3 ) .Cr &lt; = 1.5 x ULN . ( 4 ) . Serum amylase lipase &lt; = 1.5 x ULN . 6 . Signed informed consent . 1 . Previously receive receive follow medical treatment CML : 1. . Treatment Busulfan within 1 day prior study entry . 2. . Treatment interferonalpha within 2 day prior study entry . 3. . Treatment hydroxyurea within 1 day prior study entry . 4. . Treatment homoharringtonine within 14 day prior study entry . 5. . Treatment Cytosine arabinoside within 28 day prior study entry . 6. . Surgery ( Including hematopoietic stem cell transplantation therapy ) 7. . Treatment anthracyclines , etoposide within 21 day prior study entry . 2 . Treatment tyrosine kinase inhibitor ( ) arsenic reagent prior study entry 3 . Patients : ( ) pregnant , ( b ) breast feeding , ( c ) female male childbearing potential unwilling use contraceptive precaution throughout trial . 4 . Major surgery within 4 week prior randomization recover prior surgery . 5 . Patients recover toxic reaction prior similar treatment evaluate investigator . 6 . Impaired cardiac function include one following : 1 . LVEF &lt; 45 % . 2. . Complete leave bundle branch block . 3. . Use ventricularpaced pacemaker . 4. . Congenital long QT syndrome . 5. . History presence ventricular , clinically significant atrial tachyarrhythmias 6. . History presence clinically significant bradyarrhythmia . ( heart rate persistently less 50/min ) 7. . QTcF &gt; 450 msec male 470 msec female . 8. . History clinically document myocardial infarction unstable angina ( last 12 month ) . 9 . .Any severe heart disease . 7 . Patients active , uncontrolled psychiatric disorder , without insight ability exact expression . 8 . Uncontrolled medical condition : 1 . .Uncontrolled diabetes fast bloodglucose &gt; 200mg/dl ( 11.1mmol/L ) , combine symptom ( nephropathy , peripheral neuropathy ) . 2. . Uncontrolled hypertension . 3. . Active uncontrolled infection ( persistent fever worsen clinical symptom ) 9 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption test drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) . 10 . History chronic pancreatitis history acute pancreatitis within 1 year study entry . 11 . Acute chronic uncontrolled liver disease severe renal disease consider unrelated CML . 12 . Patients actively receive therapy strong CYP3A4 inhibitor , strong CYP3A4 inducer medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug . 13 . Treatment investigational agent ( define use accordance approve indication ) within 4 week prior randomization . 14 . Known allergic study drug , include crude drug adjuvant . 15 . As investigator evaluate , patient fit join study ( severe complication ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>